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Differentiation of Cardiac from Noncardiac Pleural Effusions in Cats
using Second-Generation Quantitative and Point-of-Care
NT-proBNP Measurements
M.J. Hezzell, J.E. Rush, K. Humm, E.A. Rozanski, J. Sargent, D.J. Connolly, A. Boswood, and
M.A. Oyama
Background: Pleural effusion is a common cause of dyspnea in cats. N-terminal pro-B-type natriuretic peptide (NT-
proBNP) measurement, using a first-generation quantitative ELISA, in plasma and pleural fluid differentiates cardiac from
noncardiac causes of pleural effusion.
Hypothesis/Objectives: To determine whether NT-proBNP measurements using second-generation quantitative ELISA
and point-of-care (POC) tests in plasma and pleural fluid distinguish cardiac from noncardiac pleural effusions and how
results compare to the first-generation ELISA.
Animals: Thirty-eight cats (US cohort) and 40 cats (UK cohort) presenting with cardiogenic or noncardiogenic pleural
effusion.
Methods: Prospective cohort study. Twenty-one and 17 cats in the US cohort, and 22 and 18 cats in the UK cohort were
classified as having cardiac or noncardiac pleural effusion, respectively. NT-proBNP concentrations in paired plasma and
pleural fluid samples were measured using second-generation ELISA and POC assays.
Results: The second-generation ELISA differentiated cardiac from noncardiac pleural effusion with good diagnostic accu-
racy (plasma: sensitivity, 95.2%, specificity, 82.4%; pleural fluid: sensitivity, 100%, specificity, 76.5%). NT-proBNP concen-
trations were greater in pleural fluid (719 pmol/L (134–1500)) than plasma (678 pmol/L (61–1500), P = 0.003), resulting in
different cut-off values depending on the sample type. The POC test had good sensitivity (95.2%) and specificity (87.5%)
when using plasma samples. In pleural fluid samples, the POC test had good sensitivity (100%) but low specificity (64.7%).
Diagnostic accuracy was similar between first- and second-generation ELISA assays.
Conclusions and clinical importance: Measurement of NT-proBNP using a quantitative ELISA in plasma and pleural fluid
or POC test in plasma, but not pleural fluid, distinguishes cardiac from noncardiac causes of pleural effusion in cats.
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Dyspnea secondary to pleural effusion is a commonpresenting complaint in cats, and can be the result
of a variety of disease processes, including neoplasia,
cardiac disease, pyothorax, and feline infectious peri-
tonitis.1,2 Differentiation of the underlying causes can
be challenging in dyspneic cats. These cats might
require supplementary oxygen and be too unstable to
tolerate extensive diagnostic testing. Measurement of
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
using a first-generation feline-specific quantitative ELI-
SAa in plasma3,4 and pleural fluid4 samples differenti-
ates cardiac from noncardiac causes of pleural effusion
in cats. Measurement in pleural fluid samples is a
potentially attractive alternative to measurement in
plasma, insofar as therapeutic thoracocentesis is usually
performed in cats with significant pleural effusion,
whereas venipuncture might cause additional distress to
an already dyspneic cat. In human patients, measure-
ment of NT-proBNP concentrations in pleural fluid has
high diagnostic accuracy to distinguish cardiac from
noncardiac causes of pleural effusion. Meta-analysis of
1,120 human patients revealed high sensitivity (94%,
95% confidence interval [CI]: 90–97%) and specificity
(94%, 95% CI: 89–97%) with a strong correlation
between NT-proBNP concentrations measured in
plasma and pleural fluid samples.5
Second-generation assays that measure NT-proBNP
in cats are available, including a second-generation
quantitative ELISAa and a semiquantitative point-
of-care (POC) testb that is specifically designed for
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detection of preclinical or occult forms of cardiomyopa-
thy.6 In contrast to the first-generation assay, sample
collection for the second-generation assays is performed
without the use of a protease inhibitor cocktail and spe-
cial handling and shipping requirements.c In emergent
cats, one disadvantage of the ELISA assay that is run
at a reference laboratory is that results are usually not
available until 1–2 working days after sample submis-
sion. The POC test offers patient-side semiquantitative
measurement of NT-proBNP but its utility to distin-
guish cardiac from noncardiac causes of pleural effusion
using either plasma or pleural fluid samples has not
been investigated.
The aims of this study were to determine whether
measurement of NT-proBNP in plasma or pleural fluid
samples using either the second-generation quantitative
ELISA or POC assay could distinguish cardiac from
noncardiac causes of pleural effusion, and how these
results compared to the results of a previous study
using the first-generation quantitative ELISA assay.4
Materials and Methods
The study was approved by the respective institutional animal
use and care committees and informed owner consent was
obtained. Thirty-eight cats presenting to one of two US teaching
hospitals (Matthew J. Ryan Veterinary Hospital of the University
of Pennsylvania, Philadelphia PA and the Foster Hospital for
Small Animals, Cummings School of Veterinary Medicine, Tufts
University, North Grafton, MA) with pleural effusion undergoing
thoracocentesis were prospectively recruited (US cohort). Forty
cats presenting to a UK teaching hospital (Queen Mother Hospital
for Animals, Royal Veterinary College, North Mymms, Hatfield)
with pleural effusion undergoing thoracocentesis were prospec-
tively recruited, as previously described (UK cohort).4 For both
cohorts, cats were recruited and the cause of the pleural effusion
was determined to be either cardiac or noncardiac by a board-cer-
tified cardiologist on the basis of the echocardiogram, history,
physical examination, and results of any additional diagnostic tests
performed. The cardiologist was blinded to all quantitative and
POC measurements of NT-proBNP.
Pleural fluid samples were obtained at the time of therapeutic
or diagnostic thoracocentesis. Plasma samples were collected when
venipuncture for diagnostic sampling was performed during the
same hospital visit and as close to the time of therapeutic thoraco-
centesis as was clinically practicable on the basis of feline stability.
One milliliter samples of pleural fluid and 2 milliliter samples of
blood were collected in K2-EDTA treated tubes and were cen-
trifuged at 3000 9 g for 5 minutes within 15 minutes of collection.
For the US cohort, NT-proBNP was measured in plasma using
the POC assayb within 30 minutes of centrifugation and the
remaining plasma and pleural fluid samples were each transferred
to a cryotube and frozen at 80°C for batched analysis. NT-
proBNP was measured at the reference laboratory in plasma and
pleural fluid samples using the second-generation ELISAa and in
pleural fluid samples using the POC assay. b For the UK cohort,
which was originally recruited for assessment of the first-genera-
tion NT-proBNP ELISA assay,4 NT-proBNP was measured at the
reference laboratory in plasma and pleural fluid samples using the
second-generation ELISAa and POC assayb in samples collected in
a protease inhibitor tubec and frozen at 80°C for batched
analysis.
The second-generation NT-proBNP in cat assays incorporate a
set of antibodies different from the first-generation assay that
attempt to target stable epitopes of NT-proBNP in cats.d The
lower and upper limits of detection of the reference laboratory
assay are 24 pmol/L and 1500 pmol/L, respectively. Values of NT-
proBNP less than the lower limit of detection were assigned values
of 24 pmol/L. Values of NT-proBNP greater than the upper limit
of detection were assigned values of 1500 pmol/L. All reference
laboratory samples were assayed in duplicate and the mean of the
two values used.
The POC test is a bidirectional flow ELISA that uses the same
pair of antibodies for the detection of NT-proBNP in cats as the
second-generation reference laboratory test, and its use in detect-
ing occult cardiomyopathy has been previously described.6 Briefly,
to perform the POC assay, 3 drops of plasma or pleural fluid were
mixed with 5 drops of assay conjugate and then added to the sam-
ple well of the test device. The conjugate-diluted sample was
allowed to flow across the device. Once the sample reached the
indicator window, the device was activated by the operator. This
initiated the wash and color development steps of the assay. The
relative color densities of the sample and reference spots were eval-
uated visually after 10 minutes of incubation. Positive results were
recorded when the density of the sample spot appeared equal to or
greater than that of the reference spot. Negative results were
recorded when the density of the sample spot appeared less than
that of the reference spot. The transition from negative to
positive on the POC test occurs in an NT-proBNP range of 150–
200 pmol/L.6
Statistical Analysis
Statistical analysis was performed using commercially available
software.e Data were examined graphically for normality of distri-
bution. Group-wise comparisons were performed using Mann–
Whitney tests, Wilcoxon signed-rank tests, or Fisher’s exact test,
as appropriate. Receiver operator characteristic (ROC) curves were
constructed to derive cut-offs for differentiation of cardiac from
noncardiac causes of pleural effusion in plasma and pleural fluid
samples based on results from the US cohort. Sensitivity, speci-
ficity, and positive and negative likelihood ratios were calculated.
The positive likelihood ratio is the ratio of true positives to false
positives and the negative likelihood ratio is the ratio of false neg-
atives to true negatives. A positive likelihood ratio <5 is consid-
ered a reasonable diagnostic test for ruling in a condition and a
negative likelihood ratio less than 0.2 is considered a reasonable
diagnostic test for ruling out a condition.7 By prespecified design,
the cut-off values generated from the US cohort were subsequently
tested in the UK cohort. Spearman’s rank order correlation coeffi-
cients (rho) and Bland–Altman plots were used to compare quanti-
tative ELISA measurements of NT-proBNP between plasma and
pleural fluid samples and the first- and second-generation assays.8
Results
Thirty-eight cats with pleural effusion were enrolled
in the US cohort between February and November
2014. Twenty-one cats were assigned to the cardiac
group and 17 cats were assigned to the noncardiac
group. The population characteristics of the US cohort
are presented in Table 1. No differences were detected
between groups for age, breed, body weight, heart rate,
respiratory rate, or diastolic measurements of interven-
tricular septum and left ventricular free wall thickness
(IVSd and LVFWd, respectively). Cats in the cardiac
group had significantly greater left atrial to aortic root
ratios (LA/Ao), and were significantly more likely to be
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male, to have a murmur or to have a gallop rhythm on
auscultation.
Forty cats with pleural effusion were enrolled in the
UK cohort between February 2011 and June 2012. The
study population and utility of NT-proBNP concentra-
tion using the first-generation assay have been described
previously.4 Twenty-two cats were assigned to the car-
diac group and 18 cats were assigned to the noncardiac
group. A cut-off of 213.3 pmol/L in plasma samples
had a sensitivity of 86.4% (95% confidence interval
(CI) 66.7–95.3%) and specificity of 88.9% (95% CI
67.2–96.9%), and a cut-off of 322.3 pmol/L in pleural
fluid samples had a sensitivity of 100% (95% CI 85.1–
100.0%) and a specificity of 94.4% (74.2–99%) to dis-
tinguish cardiac from noncardiac causes of pleural effu-
sion. Samples were stored at 80°C for 30–46 months
before analysis.
Results of NT-proBNP measurements in the US
cohort using the second-generation reference laboratory
ELISA and the POC test are presented in Table 2. The
result of the POC test using a plasma sample was not
available for one cat in the noncardiac group. NT-
proBNP concentrations in plasma and pleural fluid
samples were significantly higher in the cardiac group
than in the noncardiac group (P < 0.0001). The propor-
tion of positive POC results from both plasma and
pleural fluid samples was significantly higher in the car-
diac group than in the noncardiac group (P < 0.0001).
ROC curve analysis in the US cohort revealed an opti-
mal plasma NT-proBNP cut-off of ≥199 pmol/L with a
sensitivity of 95.2% (95% CI 77.3–99.2%), specificity of
82.4% (95% CI 59.0–93.8%), positive likelihood ratio
of 5.40 (95% CI 1.92–15.14), and negative likelihood
ratio of 0.06 (95% CI 0.01–0.40). The area under the
ROC curve was 0.952 (95% CI 0.891–1.00). A pleural
fluid NT-proBNP cut-off of ≥240 pmol/L yielded a sen-
sitivity of 100% (95% CI 84.5–100%), specificity of
76.5% (95% CI 52.7–90.4), and positive likelihood ratio
of 4.25 (95% CI 1.80–10.01). The negative likelihood
ratio could not be calculated because all 21 cats with
pleural effusion of cardiac origin had pleural fluid NT-
proBNP ≥240 pmol/L. The area under the pleural fluid
ROC curve was 0.923 (95% CI 0.832–1.00). There was
no significant difference between the area under the
pleural fluid ROC curve and the area under the plasma
ROC curve (P = 0.26).
In the US cohort, the POC test using plasma sam-
ples differentiated the cardiac and noncardiac groups
with a sensitivity of 95.2% (95% CI 77.3–99.2%),
specificity of 87.5% (95% CI 64.0–96.5%), positive
likelihood ratio of 7.62 (95% CI 2.08–27.95), and neg-
ative likelihood ratio of 0.05 (95% CI 0.01–0.37). The
area under the ROC curve for the POC assay using
plasma samples was 0.914 (95% CI 0.818–1.00). The
POC test using pleural fluid samples differentiated the
cardiac and noncardiac groups with a sensitivity of
100% (95% CI 84.5–100%), specificity of 64.7% (95%
CI 41.3–82.7%), and positive likelihood ratio of 2.83
(95% CI 1.49–5.39) in the US cohort. The negative
likelihood ratio could not be calculated because all 21
cats with pleural effusion of cardiac origin had a posi-
tive POC assay. The area under the ROC curve for
the POC assay using pleural fluid samples was 0.824
(95% CI 0.706–0.941) and was not statistically differ-
ent from the area under the ROC curve for plasma
samples (P = 0.096).
Results of NT-proBNP measurements in the UK
cohort using the second-generation reference laboratory
ELISA and the POC test are presented in Table 3.
Insufficient plasma sample volume was available to
measure NT-proBNP using the second-generation ver-
sion of the ELISA in 3 cats and using the POC test in 6
cats. When the cut-off values derived from the US
Table 1. Characteristics of the cardiac and noncardiac groups in the US cohort. The median and ranges are shown
for continuous variables. NB sex was not recorded for one cat in the cardiac group.
Variable Noncardiac (n = 17) Cardiac (n = 21) P value
Age (years) 12.0 (0.5–16.0) 12.0 (1.5–18.0) 0.86
Pedigree breed (yes/no) 2/15 1/20 0.58
Sex (male/female) (n = 37) 6/11 16/4 0.008
Weight (kg) 4.1 (2.1–8.8) 4.9 (2.7–6.9) 0.74
Heart rate (beats per minute) 200 (160–260) 180 (130–300) 0.27
Respiratory rate (breaths per minute) 68 (44–92) 60 (30–88) 0.17
Murmur (yes/no) 5/12 15/6 0.021
Gallop (yes/no) 1/16 13/8 0.001
LA/Ao 1.3 (1.0–1.9) 2.6 (1.6–3.2) <0.001
IVSd (mm) (n = 35) 5.5 (3.5–7.5) 6.2 (3.7–10.0) 0.37
LVFWd (mm) (n = 35) 5.8 (2.9–11.0) 7.2 (3.8–18.6) 0.16
Table 2. Results of NT-proBNP measurements for the
cardiac and noncardiac groups using 2 assay methods
for the US cohort. The median and interquartile ranges
are shown for continuous variables.
Cardiac (n = 21)
Noncardiac
(n = 17) P value
Second-generation ELISA (pmol/L)
Plasma 1500 (790–1500) 58 (31–174.5) <0.0001
Pleural fluid 1500 (918–1500) 108 (56–324.5) <0.0001
Point-of-care test (no. positive/no. negative)
Plasma (n = 37) 20/1 2/14 <0.0001
Pleural fluid 21/0 6/11 <0.0001
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cohort were applied to plasma and pleural fluid mea-
surements of NT-proBNP using the second-generation
assay from the UK cohort, plasma NT-proBNP
≥199 pmol/L yielded a sensitivity of 95.0% (95% CI
76.4–99.1%), specificity of 82.4% (95% CI 59.0–
93.8%), positive likelihood ratio of 5.40 (95% CI 1.92–
15.11), and negative likelihood ratio of 0.06 (95% CI
0.01–0.42). Pleural fluid NT-proBNP ≥240 pmol/L
yielded a sensitivity of 100% (95% CI 85.1–100%),
specificity of 66.7% (95% CI 43.8–83.7%), and positive
likelihood ratio of 3.00 (95% CI 1.56–5.77). The nega-
tive likelihood ratio could not be calculated because all
22 cats with pleural effusion of cardiac origin had pleu-
ral fluid NT-proBNP ≥240 pmol/L. For both plasma
and pleural fluid samples, the 95% CI of the sensitivity
and specificity of the second-generation ELISA assay
overlapped with reported confidence intervals using the
first-generation ELISA assay.4 In the UK cohort, the
POC test using plasma samples differentiated cardiac
from noncardiac causes of pleural effusion with a sensi-
tivity of 88.2% (95% CI 65.7–96.7%), specificity of
88.2% (95% CI 65.7–96.7%), positive likelihood ratio
of 7.50 (95% CI 2.02–27.89), and negative likelihood
ratio of 0.13 (95% CI 0.04–0.50). The POC test using
pleural fluid samples differentiated cardiac from noncar-
diac causes of pleural effusion with a sensitivity of
100% (95% CI 85.1–100%), specificity of 77.8% (95%
CI 54.8–91.0%), and positive likelihood ratio of 4.50
(95% CI 1.89–10.68). The negative likelihood ratio
could not be calculated because all 22 cats with pleural
effusion of cardiac origin had a positive POC assay.
NT-proBNP concentrations in paired plasma and
pleural fluid samples from the US cohort were mea-
sured using the second-generation ELISA assay, and
were significantly correlated (Spearman rho = 0.969;
P < 0.0001); however, the limits of agreement between
the two sample types were wide, and NT-proBNP con-
centrations in pleural fluid were systematically greater
than those in plasma samples (pleural fluid, 719 pmol/L
[134–1500] versus plasma, 678 pmol/L [61–1500];
P = 0.003) with a mean bias of +67.9 pmol/L (Fig 1).
NT-proBNP concentrations in plasma samples from the
UK cohort using the first- and second-generation
ELISA assay were significantly correlated (Spearman
rho = 0.864; P < 0.0001); however, the limits of agree-
ment between the two assay generations were wide, and
NT-proBNP concentrations in plasma assayed using the
second-generation assay were systematically greater
than those in plasma samples assayed using the first-
generation assay (plasma second-generation, 531 pmol/
L (84–874) versus plasma first-generation 254 pmol/L
(50–620); P = 0.002), with a mean bias of +156.1 pmol/
L (Fig 2). NT-proBNP concentrations in pleural fluid
samples from the UK cohort using the first- and sec-
ond-generation ELISA assay were significantly corre-
lated (Spearman rho = 0.966; P < 0.0001). Pleural fluid
NT-proBNP concentrations were not significantly differ-
ent between the two different generations of NT-
proBNP ELISA assay (pleural second generation,
603 pmol/L (121–1135) versus pleural first generation
542 pmol/L (142–1374); P = 0.95).
Discussion
This study utilized data from two separate cohorts to
investigate the diagnostic characteristics of a quantita-
tive ELISA and semiquantitative POC test to differenti-
ate cardiac and noncardiac causes of pleural effusion in
cats. Our results demonstrate that measurement of NT-
proBNP in plasma samples using either a quantitative
ELISA or POC test differentiates these etiologies of
pleural effusion with good diagnostic accuracy. Mea-
surement of NT-proBNP concentration in pleural fluid
samples using the quantitative ELISA also had good
diagnostic accuracy as long as a higher cut-off value is
used for pleural fluid samples (≥240 pmol/L) compared
to the cut-off value used for plasma samples
(≥199 pmol/L). In the emergency setting, POC testing
of either plasma or pleural fluid is attractive because of
the immediacy of assay results. Testing of pleural effu-
sion, specifically, is attractive in instances in which cats
with significant pleural effusion would undergo thera-
peutic thoracocentesis but might not be stable enough
for venipuncture. However, the results of this study sug-
gest that the diagnostic value of POC testing of pleural
effusion samples is limited. Using pleural fluid samples,
a negative POC assay result helped to rule out cardiac
causes of pleural effusion, but a positive result was
associated with a relatively low positive predictive value,
and the likelihood ratio associated with a positive pleu-
ral fluid POC test from either the US or UK cohort
(i.e., 2.83 and 4.5) was lower than the level (i.e. 5.0)
generally considered to indicate a useful diagnostic test.7
Thus, a positive POC result using pleural fluid samples
frequently represents a false positive result, and this lim-
its its diagnostic value. The discrepancy in performance
between testing plasma and pleural fluid samples using
the POC test probably reflects the NT-proBNP concen-
tration at which the POC device transitions from a neg-
ative to positive result. A previous study has shown this
to occur at a NT-proBNP concentration between 150
and 200 pmol/L,6 which approximates the cut-off value
in plasma (199 pmol/L) but is lower than the optimal
cut-off for pleural fluid samples (240 pmol/L) found in
this study.
Table 3. Results of NT-proBNP measurements for the
cardiac and noncardiac groups using 2 assay methods
for the UK cohort. The median and interquartile ranges
are shown for continuous variables.
Cardiac
(n = 22)
Noncardiac
(n = 18) P value
Second-generation ELISA (pmol/L)
Plasma 849 (590–1500)
(n = 20)
73 (33–138)
(n = 17)
<0.0001
Pleural fluid 1001 (640–1500)
(n = 22)
98 (45–273)
(n = 18)
<0.0001
Point-of-care test (no. positive/no. negative)
Plasma (n = 34) 15/2 2/15 <0.0001
Pleural fluid (n = 40) 22/0 4/14 <0.0001
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Likelihood ratios can be used to estimate post-test
probability of pleural effusion of cardiac cause. In this
study, plasma POC test results were associated with
approximate positive and negative likelihood ratios of
7.50 and 0.10, respectively. These values roughly trans-
late into an absolute increase or decrease in the post-
test probability for a cardiac cause of pleural effusion
of 40% compared to the pretest probability.9 For
example, in a population of cats whose pretest proba-
bility of pleural effusion because of a cardiac cause is
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Fig 1. Bland–Altman plot illustrating agreement between measurements of NT-proBNP concentrations in pleural fluid and plasma sam-
ples in cats using the second-generation assay in samples from the US cohort. The mean bias and the dash-dot lines representing the 95%
confidence intervals for the bias indicate that the NT-proBNP concentration of pleural fluid samples was on average 67.9 pmol/L greater
than NT-proBNP concentration from paired plasma sample. The 95% limits of agreement between the two sample types are displayed as
1.96 times the standard deviation of the difference.
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Fig 2. Bland–Altman plot illustrating agreement between measurements of NT-proBNP concentrations in plasma samples from cats using
the first- and second-generation assay in samples from the UK cohort. The mean bias and the dash-dot lines representing the 95% confi-
dence intervals for the bias indicate that the NT-proBNP concentration of plasma samples using the second-generation assay was on aver-
age 156.1 pmol/L greater than NT-proBNP concentration from paired plasma sample using the first generation assay. The 95% limits of
agreement between the two sample types are displayed as 1.96 times the standard deviation of the difference.
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60%, a positive plasma POC test would increase this
probability to nearly 100% while a negative plasma
POC test result would reduce the probability to 20%.
Likewise, in a population of cats where a cardiac cause
of pleural effusion is 10%, and hence unlikely, a posi-
tive POC test increases this probability to only 50%. It
is therefore important, as with any clinical test, that
measurements of NT-proBNP be interpreted in combi-
nation with historical and physical examination findings
and the results of other diagnostic tests such as imaging
and not be relied upon in isolation for clinical decision-
making.
The optimal cut-offs determined in this study are
somewhat lower than those previously reported. Cut-
offs for differentiation of cardiac from noncardiac
causes of dyspnea using plasma samples have been
reported as 220 pmol/L,10 265 pmol/L,11 214 pmol/L4
and 258 pmol/L.3 The former two studies did not
restrict inclusion to cats with pleural effusion, whereas
the latter two did; all of these studies used the first-
generation quantitative ELISA. A cut-off for pleural
fluid samples of 322 pmol/L has been reported to dis-
tinguish cardiac and noncardiac causes of dyspnea
using the first-generation ELISA.4 Given that plasma
measurements of NT-proBNP were found to be higher
using the second- compared with the first-generation
ELISA and that no difference was found in pleural
fluid measurements between assay generations, it seems
surprising that the optimal cut-offs were lower in this
study than those previously reported. However, this
probably reflects the relatively small sample sizes in
each study, population differences (United states ver-
sus United Kingdom versus Germany) and differences
in the methods used to select the optimal cut-off val-
ues.
This study revealed that NT-proBNP concentrations
were significantly higher in pleural fluid samples than
in plasma samples when measured using the quantita-
tive second-generation ELISA, resulting in the need for
two different cut-off values depending on sample type.
These findings agree with a previous study that com-
pared pleural fluid and plasma samples in cats using
the first-generation assay,4 but are in contrast to
human patients, in whom pleural fluid and plasma NT-
proBNP concentrations are reported to be almost iden-
tical.12 The potential reasons for this discrepancy
between species are not immediately clear. In this
study, plasma NT-proBNP concentrations were signifi-
cantly higher using the second-generation versus the
first-generation assay, whereas in contrast NT-proBNP
concentrations in pleural fluid samples were not signifi-
cantly different between assay generations. One possible
explanation is that the rate of postsample degradation
is lower in pleural fluid than in plasma samples, per-
haps because of lower concentrations of protease
enzymes. Further studies are necessary to investigate
this possibility.
This study has a number of important limitations.
While attempts were made to collect plasma and pleu-
ral fluid samples at the same time, feline instability
might have caused pleural fluid and blood samples to
be obtained hours apart from each other. Cats were
assigned to the cardiac or noncardiac groups based on
the opinion of the blinded cardiologist, and misclassifi-
cation of cases could have occurred. This study
involved use of different sample collection, handling
and storage protocols; however, samples collected for
ELISA from the US cohort were handled according to
current manufacturer recommendations and results
between the US and UK cohorts were comparable.
The pleural fluid POC tests from both the US and UK
cohorts were performed on batched samples which had
been stored at 80°C, and further studies that utilize
the POC test in pleural fluid samples in a truly pet-side
manner, including comparison of assay performance
when used immediately, compared with on previously
frozen samples, should be performed. Pleural fluid
sample POC testing was not performed immediately in
this study because the POC device had not been vali-
dated for use with pleural fluid samples at the time of
sample collection. One disadvantage of using the POC
device is that the result is either positive or negative;
this is in contrast to the quantitative ELISA, which
allows for interpretation of the results throughout a
range of possible values. The POC device is not specifi-
cally designed to differentiate causes of pleural effusion
in cats, but rather to detect occult cardiomyopathy in
cats without obvious respiratory signs, and the device’s
cut-off value between a negative and positive result is
relatively low for differentiation of cardiac versus non-
cardiac etiologies of pleural effusion. Nevertheless, the
POC assay when used with plasma was able to differ-
entiate cause of pleural effusion with good diagnostic
accuracy.
In conclusion, the results of this study suggest that
quantitative measurements of NT-proBNP in plasma
and pleural fluid samples using a second-generation
assay allow differentiation of cardiac from noncardiac
causes of pleural effusion with good diagnostic accu-
racy. Cut-off values specific for sample type should be
used. Measurement of NT-proBNP in plasma samples
using a POC test also allows differentiation of cardiac
from noncardiac causes of pleural effusion with good
diagnostic accuracy; however, although sensitivity is
excellent and a negative POC result in pleural fluid
samples helps rule out a cardiac cause of pleural effu-
sion, the specificity of the POC test is low, resulting in
a low positive predictive value. Measurements of NT-
proBNP in plasma fluid samples obtained using the sec-
ond-generation assay are systematically greater than
those obtained using the first-generation assay, and cut-
offs specific to the second-generation assay should be
used.
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Footnotes
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brook, ME
b SNAP Feline proBNP, IDEXX Laboratories Inc., Westbrook,
ME
c Cardiopet proBNP specimen tubes, IDEXX Laboratories Inc.,
Westbrook, ME
d Mainville et al. Analytical validation of an immunoassay for the
quantification of N-terminal pro-B-type natriuretic peptide in
feline blood. Journal of Veterinary Diagnostic Investigation (In
Press).
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ware, Ostend, Belguim
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